IL204442A - Inhibitors of atpase-0fif, medicinal preparations containing them and their use - Google Patents

Inhibitors of atpase-0fif, medicinal preparations containing them and their use

Info

Publication number
IL204442A
IL204442A IL204442A IL20444210A IL204442A IL 204442 A IL204442 A IL 204442A IL 204442 A IL204442 A IL 204442A IL 20444210 A IL20444210 A IL 20444210A IL 204442 A IL204442 A IL 204442A
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
atpase inhibitors
atpase
inhibitors
pharmaceutical
Prior art date
Application number
IL204442A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of IL204442A publication Critical patent/IL204442A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL204442A 2007-09-14 2010-03-11 Inhibitors of atpase-0fif, medicinal preparations containing them and their use IL204442A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97255307P 2007-09-14 2007-09-14
PCT/US2008/076021 WO2009036175A2 (en) 2007-09-14 2008-09-11 F1f0-atpase inhibitors and related methods

Publications (1)

Publication Number Publication Date
IL204442A true IL204442A (en) 2015-05-31

Family

ID=40452820

Family Applications (1)

Application Number Title Priority Date Filing Date
IL204442A IL204442A (en) 2007-09-14 2010-03-11 Inhibitors of atpase-0fif, medicinal preparations containing them and their use

Country Status (11)

Country Link
US (1) US8324258B2 (cg-RX-API-DMAC7.html)
EP (1) EP2200977B1 (cg-RX-API-DMAC7.html)
JP (1) JP5416122B2 (cg-RX-API-DMAC7.html)
CN (1) CN101855203B (cg-RX-API-DMAC7.html)
AU (1) AU2008298870C1 (cg-RX-API-DMAC7.html)
CA (1) CA2698248C (cg-RX-API-DMAC7.html)
ES (1) ES2614498T3 (cg-RX-API-DMAC7.html)
IL (1) IL204442A (cg-RX-API-DMAC7.html)
MX (1) MX2010002732A (cg-RX-API-DMAC7.html)
NZ (1) NZ583689A (cg-RX-API-DMAC7.html)
WO (1) WO2009036175A2 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5127096B2 (ja) 1999-04-30 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
EP1948191B1 (en) 2005-11-01 2013-01-16 The Regents of the University of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
KR101164718B1 (ko) 2007-03-09 2012-07-11 더 리젠츠 오브 더 유니버시티 오브 미시간 신규 화합물 및 이의 표적에 관한 조성물 및 방법
MX2010002732A (es) 2007-09-14 2010-06-02 Univ Michigan Inhibidores de f1f0-atpasa y metodos relacionados.
CN101918375A (zh) 2007-11-06 2010-12-15 密歇根大学董事会 在皮肤病症的治疗中有用的苯并二氮杂*酮化合物
US8497307B2 (en) 2008-09-11 2013-07-30 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
WO2010121164A2 (en) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
EP2470020A4 (en) 2009-09-18 2013-03-13 Univ Michigan BENZODIAZEPINONE COMPOUNDS AND TREATMENT METHODS THEREWITH
WO2011062765A2 (en) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
JP5856064B2 (ja) 2009-11-17 2016-02-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物
DK2648511T3 (en) * 2010-12-08 2017-09-18 Lycera Corp PYRAZOLYLGUANIDINE-F1F0 ATPASE INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF
WO2012078867A2 (en) * 2010-12-08 2012-06-14 Lycera Corporation Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
MX2013006398A (es) * 2010-12-08 2013-12-02 Lycera Corp Inhibidores de f1f0-atpasas de tipo piridonilguanidina y usos terapeúticos.
US9169199B2 (en) 2010-12-08 2015-10-27 Lycera Corporation Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
US9221814B2 (en) 2012-06-08 2015-12-29 Lycera Corporation Heterocyclic guanidine F1F0-atpase inhibitors and therapeutic uses thereof
US9920012B2 (en) 2012-06-08 2018-03-20 Lycera Corporation Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
US9580391B2 (en) 2012-06-08 2017-02-28 Lycera Corporation Saturated acyl guanidine for inhibition of F1F0-ATPase
WO2014015157A2 (en) 2012-07-19 2014-01-23 Philadelphia Health & Education Corporation Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
EP3080088B1 (en) 2013-12-10 2019-07-31 Lycera Corporation Alkylpyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
WO2015089152A1 (en) 2013-12-10 2015-06-18 Lycera Corporation N-substituted pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
MX2016007445A (es) 2013-12-10 2016-09-09 Lycera Corp Inhibidores de f1f0-atpasa de trifluorometil pirazolil guanidina y usos terapeuticos de los mismos.
MX376974B (es) * 2016-02-19 2025-03-07 Phoenix Molecular Designs Derivados de carboxamida útiles como inhibidores de rsk.
WO2019089902A1 (en) 2017-11-01 2019-05-09 Drexel University Compounds, compositions, and methods for treating diseases
CN108486117B (zh) * 2018-04-27 2020-09-08 浙江大学 一种rna抑制剂及其在抑制f1f0-atp合成酶活性中的应用
CA3129722A1 (en) 2019-02-11 2020-08-20 Phoenix Molecular Designs Crystalline forms of an rsk inhibitor

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US802394A (en) 1905-07-27 1905-10-24 Harry W Hill Base-plate for shaft-bearing stands and the like.
US2457405A (en) 1945-09-25 1948-12-28 Monsanto Chemicals Halo nitroparaffin modified aminoplasts
US3261828A (en) 1962-10-04 1966-07-19 Hoffmann La Roche 3h-1,4-benzodiazepine-2,5(1h,4h)-dione compounds
US3374264A (en) * 1962-10-04 1968-03-19 Hoffmann La Roche N-haloacetyl-anthranilic acids and esters
US3415814A (en) 1966-09-28 1968-12-10 Sterling Drug Inc 4-(cyclopropylmethyl)-3h-1,4-benzodiazepine-2,5(1h,4h)-dione
US3384635A (en) 1966-09-28 1968-05-21 Sterling Drug Inc 1, 4-benzodiazepine derivatives
AT280290B (de) 1967-11-24 1970-04-10 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen 1-Phenyl-4-alkyl-3H-1,4-benzodiazepin-2,5-[1H,4H]-dionen
US4108852A (en) 1969-03-18 1978-08-22 Knoll Ag. Process for preparing 1,5-benzodiazepine-2-ones
USRE30293E (en) * 1969-03-18 1980-06-03 Knoll A.G. Process for preparing 1,5-benzodiazepine-2-ones
GB1363735A (en) 1970-10-23 1974-08-14 Hoechst Ag Process for the manufacture of benzimidazolones
GB1324469A (en) 1970-10-28 1973-07-25 Knoll Ag Derivatives of benzodiazepines
ZA7468B (en) 1973-01-16 1974-11-27 J Voorhees Compositions and treatment of proliferatave skin diseases with phosphodiesterase inhibitors
IE38931B1 (en) 1973-03-09 1978-07-05 Lipha Triazolobenzodiazepines
US4076823A (en) 1977-08-18 1978-02-28 E. R. Squibb & Sons, Inc. Triazolo-2,4-benzodiazepines
JPS59112984A (ja) 1982-12-21 1984-06-29 Shionogi & Co Ltd １，４−ベンゾジアゼピン誘導体
US4495101A (en) 1983-04-28 1985-01-22 American Home Products Corporation Antiinflammatory 5H-tetrazolo (5,1-c)(1,4)benzodiazepine derivatives
US4551480A (en) 1983-06-21 1985-11-05 Stiefel Laboratories, Inc. Compositions for the treatment of psoriasis
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US4820834A (en) 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
US5004741A (en) 1984-06-26 1991-04-02 Merck & Co., Inc. Methods of antagonizing CCK or gastrin with benzodiazepine analogs
DE3435974A1 (de) * 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
FR2591596B1 (fr) 1985-12-13 1988-09-09 Roussel Uclaf Nouvelles 4h-triazolo(4,3-a)(1,4)benzodiazepines, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4751223A (en) 1986-10-14 1988-06-14 Hoechst-Roussel Pharmaceuticals, Inc. Antiinflammatory and analgesic aminoalkyl tetracyclic benzodiazepines
US4898861A (en) 1987-03-26 1990-02-06 Hoffmann-La Roche Inc. Method for inhibiting the proliferation of tumor cells
US5147872A (en) * 1987-06-09 1992-09-15 Golwyn Daniel H Treatment of immunologically based disorders, specifically psoriasis
US4970207A (en) 1988-07-07 1990-11-13 Fujisawa Pharmaceutical Company, Ltd. Benzodiazepine derivatives
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5041438A (en) 1989-10-30 1991-08-20 Hoffmann-La Roche Inc. Method for treating retroviral infections with benzodiazepine compounds
US5324726A (en) 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
ATE145208T1 (de) 1990-07-06 1996-11-15 Yoshitomi Pharmaceutical Kondensierte thiophenverbindungen und deren verwendung
BR9200951A (pt) 1991-03-21 1992-11-17 Hoffmann La Roche Compostos, processo para sua producao,preparacoes farmaceuticas e uso
EP0637308A1 (en) 1992-03-16 1995-02-08 MERCK SHARP & DOHME LTD. Benzodiazepine derivatives, compositions containing them and their use in therapy
US5599352A (en) 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
GB9307527D0 (en) 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US5391566A (en) * 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
WO1996005827A1 (en) 1994-08-18 1996-02-29 Merck & Co., Inc. N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5444092A (en) 1994-07-20 1995-08-22 Collins; Jerry Method and composition for treating psoriasis
JPH10504545A (ja) 1994-07-29 1998-05-06 藤沢薬品工業株式会社 ベンゾジアゼピン誘導体
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
US5677282A (en) * 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
US5962337A (en) 1995-06-29 1999-10-05 Pharmacopeia, Inc. Combinatorial 1,4-benzodiazepin-2,5-dione library
RU2096044C1 (ru) 1995-07-19 1997-11-20 Малое предприятие "Ветта" Ветеринарный имплантируемый препарат для регулирования биологического ритма животных
US5776946A (en) 1995-08-28 1998-07-07 Mcgeer; Patrick L. Peripheral benzodiazepine receptor ligands as antiinflammatory agents
JP2001520636A (ja) 1995-08-30 2001-10-30 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 慢性炎症性疾患における細胞蓄積の治療
CA2233012A1 (en) 1995-09-21 1997-03-27 Koichi Shudo Compounds enhancing the activity of retinoids
US6579854B1 (en) 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US7351421B2 (en) * 1996-11-05 2008-04-01 Hsing-Wen Sung Drug-eluting stent having collagen drug carrier chemically treated with genipin
PT945445E (pt) 1996-12-10 2004-01-30 Zeria Pharm Co Ltd Derivados de 1,5-benzodiazepina
US6074859A (en) 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
US6080568A (en) 1997-08-19 2000-06-27 Genencor International, Inc. Mutant α-amylase comprising modification at residues corresponding to A210, H405 and/or T412 in Bacillus licheniformis
AU750245B2 (en) 1997-10-08 2002-07-11 Aurinia Phamaceuticals Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6206914B1 (en) 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US20030044776A1 (en) 1998-09-25 2003-03-06 James A. Dykens Compositions and methods for identifying agents that alter mitochondrial permeability transition pores
FR2785803B1 (fr) 1998-11-17 2005-03-25 Sanofi Sa Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes
US7175953B2 (en) * 1999-04-09 2007-02-13 Institute Fuer Diagnostik Forschung Short-warp peptide-dye conjugate as contrast agent for optical diagnostic
JP5127096B2 (ja) 1999-04-30 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用
US20030119029A1 (en) 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20040176358A1 (en) 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20050113460A1 (en) 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7276348B2 (en) 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
AU5826100A (en) 1999-07-13 2001-01-30 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
US6524623B1 (en) 1999-11-12 2003-02-25 Milton Hodosh Therapeutic compositions and methods of use thereof
DE60117777T2 (de) 2000-05-11 2006-08-17 Eastman Chemical Co., Kingsport Acylierte zyclodextrin guest-inklusion komplexe
US20020048566A1 (en) 2000-09-14 2002-04-25 El-Deiry Wafik S. Modulation of cellular apoptosis and methods for treating cancer
CA2432825A1 (en) 2000-12-15 2002-06-20 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
CA2446696A1 (fr) * 2001-06-07 2002-12-12 Neuro3D Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs
EP1423122A4 (en) 2001-08-15 2008-12-10 Univ Michigan COMPOSITIONS AND METHODS RELATED TO NEW BENZODIAZEPINE COMPOUNDS AND THEIR OBJECTIVES
US6916813B2 (en) * 2001-12-10 2005-07-12 Bristol-Myers Squibb Co. (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
US20040009972A1 (en) 2002-06-17 2004-01-15 Ding Charles Z. Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
US7150433B2 (en) * 2002-08-16 2006-12-19 Toyota Motor Sales, U.S.A., Inc. Aircraft bolster trays
US20040087489A1 (en) 2002-11-06 2004-05-06 Antonio Ruiz Compositions and methods for the treatment of mycobacterial infections
US7745431B2 (en) 2002-12-03 2010-06-29 Vela Acquisition Corporation Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof
US7365070B2 (en) * 2002-12-04 2008-04-29 Ore Pharmaceuticals Inc. Modulators of melanocortin receptor
CA2524394C (en) 2003-05-01 2011-07-12 The Regents Of The University Of Michigan Novel benzodiazepine compounds, compositions and uses thereof
US7351241B2 (en) 2003-06-02 2008-04-01 Carl Zeiss Meditec Ag Method and apparatus for precision working of material
US20090275099A1 (en) 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20050272723A1 (en) 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
WO2006007532A2 (en) 2004-07-01 2006-01-19 Synta Pharmaceuticals Corp. 2-substituted heteroaryl compounds
US20060052369A1 (en) 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
JP2008528448A (ja) 2005-01-03 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 新規化合物に関連する組成物および方法、ならびにその標的
JP2008545757A (ja) 2005-06-01 2008-12-18 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 溶媒和されていないベンゾジアゼピン組成物および方法
EP1742460A1 (en) 2005-06-18 2007-01-10 TTE Germany GmbH Raster distortion correction circuit
US20070105844A1 (en) 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
EP1951050A4 (en) 2005-10-26 2011-04-27 Univ Michigan THERAPEUTIC COMPOSITIONS AND METHOD
EP1948191B1 (en) 2005-11-01 2013-01-16 The Regents of the University of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
US7759338B2 (en) 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
EP2418206A3 (en) 2006-06-09 2012-06-27 The Regents of the University of Michigan Benzodiazepine derivatives useful in the treatment of autoimmune disorders
GB0615068D0 (en) 2006-07-28 2006-09-06 Ttp Communications Ltd Digital radio systems
KR101164718B1 (ko) * 2007-03-09 2012-07-11 더 리젠츠 오브 더 유니버시티 오브 미시간 신규 화합물 및 이의 표적에 관한 조성물 및 방법
MX2010002732A (es) 2007-09-14 2010-06-02 Univ Michigan Inhibidores de f1f0-atpasa y metodos relacionados.
CN101918375A (zh) 2007-11-06 2010-12-15 密歇根大学董事会 在皮肤病症的治疗中有用的苯并二氮杂*酮化合物
CN111381371B (zh) 2018-12-27 2022-04-15 中强光电股份有限公司 头戴式显示装置

Also Published As

Publication number Publication date
US8324258B2 (en) 2012-12-04
EP2200977A2 (en) 2010-06-30
EP2200977B1 (en) 2016-11-09
AU2008298870A1 (en) 2009-03-19
CN101855203A (zh) 2010-10-06
US20100222400A1 (en) 2010-09-02
CA2698248A1 (en) 2009-03-19
NZ583689A (en) 2012-04-27
JP2011509238A (ja) 2011-03-24
MX2010002732A (es) 2010-06-02
CA2698248C (en) 2017-08-29
EP2200977A4 (en) 2011-12-28
JP5416122B2 (ja) 2014-02-12
CN101855203B (zh) 2014-03-19
AU2008298870C1 (en) 2014-10-09
AU2008298870B2 (en) 2014-04-10
WO2009036175A3 (en) 2009-05-07
ES2614498T3 (es) 2017-05-31
WO2009036175A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
IL204442A (en) Inhibitors of atpase-0fif, medicinal preparations containing them and their use
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
IL210843A0 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IL211018A (en) Inhibitors, processes for making them, medicinal preparations containing them and their use
IL214175A (en) Derivatives of aminotetralin, their pharmaceutical compositions and their use
GB2450753B (en) New Pharmaceutical formulation
IL197933A (en) Knaase inhibitors, pharmaceuticals containing them and their uses
IL216254A (en) Compounds, pharmaceutical compositions and their uses
EP2056835A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
IL204844A (en) Coinolone analogues, pharmaceuticals containing them and their uses
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
IL199397A (en) Hetero-ring compounds, pharmaceuticals containing them, and their medicinal products
IL192613A (en) Cycloalkylamines and their pharmaceutical compositions
IL215799A (en) Quinazolone compounds, pharmaceuticals containing them and their uses
IL194546A0 (en) Arylaminopyridine derivatives and pharmaceutical compositions containing them
IL206808A (en) Indolyl-pyridone history, their pharmaceutical preparations and their uses
IL200616A0 (en) Co-crystals and pharmaceutical compositions comprising the same
IL206594A (en) The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
IL200885A (en) A history of mannich-based compounds and pharmacological preparations including them
SI2154966T1 (sl) Benzimidazoli in njihovi farmacevtski sestavki
IL216113A (en) Processed derivatives of indazole and azaza-indazole, pharmaceutical preparations containing them and their uses
IL200153A (en) History of Ethnon, including and use of pharmaceutical preparations
IL193211A (en) Derivatives of Indzol-Troaril and pharmaceutical preparations containing them
IL195813A0 (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
IL210316A (en) History of Triazol Pharmacopoeias that contain them and their uses

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed